Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
SPRUCE BIOSCIENCES, INC. (SPRB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH South San Francisco, Calif. – August 14, 2023 – Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. “Our goal with the POWER..."
05/15/2023 8-K Quarterly results
Docs: "Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled South San Francisco, Calif. – May 15, 2023 – Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. “I am pleased by the me..."
11/10/2022 8-K Quarterly results
Docs: "Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vice President of Clinical Development"
08/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
Docs: "Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates Topline Safety Data from Cohort 1 of Pediatric Classic CAH Study Expected by 1H 2023 Will Charlton, M.D., M.A.S., Appointed Chief Medical Officer"
08/10/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
11/18/2020 8-K Quarterly results
Docs: "Press Release of Spruce Biosciences, Inc."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy